The 700-page Part D proposed rule does much more than change the "protected" class list. Among many other provisions, it spells out how CMS interprets the infamous "non-interference" clause.
You can't accuse CMS of shying away from a fight.
A proposed rule on changes to Medicare Part D is bound to trigger a lot of feedback for the Centers...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
CMS Administrator Oz punted on a GLP-1 question in an interview, suggesting it was because his agency will be acting soon.
For manufacturers, the model could lead to a substantial reductions in prices for high cost physician administered drugs in Medicare, Medicaid and the 340B program.
Pink Sheet reporter and editors discuss the issues that could arise for the FDA as it navigates the government shutdown, as well as the aftershocks of Pfizer’s drug pricing deal with the White House.
CMS said the policy may be modified next year in rulemaking on the negotiation program.
The FDA’s search for hundreds of new employees, as well as the CMS Most Favored Nation pricing demonstration project, could be delayed by the ongoing government shutdown.
By choosing a confidential agreement with the US government over announcing the details of the deal, Pfizer continues industry’s legacy of pricing secrecy.
The company’s agreement with the Trump Administration, which likely is a template for MFN deals with other companies, also includes a $70bn commitment to ‘reshoring’ development and manufacturing in the US.
